Replies to post #165076 on Biotech Values

[DewDiligence]

XOMA—You completely missed my point. --- "Initial indication" "Priming"

I didn’t miss the point—I just don’t agree with it. Behçet’s is an ultra-orphan indication that couldn’t possibly support profitability, and the pricing would eventually have to come down to cater to the larger NIU market.

A BLA based on only the Behçet’s trial is not an intentional ploy for “priming the market”—it’s simply spin to make a bad situation seem less so.